The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Diabetic nephropathy is the most common cause of end-stage renal disease in the developed world. Angiotensin-converting enzyme inhibitors have been demonstrated to be renoprotective in type I diabetes and are now the standard of care for both hypertensive and non-hypertensive type I diabetic patients with any level of proteinuria. The role of blockade of the renin-angiotensin system in type II diabetic patients is not defined. The Collaborative Study Group has initiated the Irbesartan Type II Diabetic Nephropathy Trial (IDNT), studying the effect of the angiotensin II receptor antagonist irbesartan on progression of renal disease and mortality in type II diabetic patients with overt nephropathy and hypertension. Here we report the study design and baseline patient characteristics. METHODS: To qualify, hypertensive type II patients, age 30-70 years, must have a 24 h urinary protein excretion of >900 mg and a serum creatinine 90-265 micromol/l (1.0-3. 0 mg/dl) in women and 110-265 micromol/l (1.2-3.0 mg/dl) in men. Three treatment arms include irbesartan, placebo and amlodipine, with every attempt made to achieve similar blood pressure levels in all treatment arms. A total of 1650 patients will be enrolled utilizing approximately 225 clinics worldwide. The primary outcome measure is time to event to the composite end-point of doubling of serum creatinine, end-stage renal disease or death. The secondary outcome measure is time to composite end-point of fatal or non-fatal cardiovascular events. The average length of patient follow-up is expected to be approximately 36 months. RESULTS: The baseline characteristics of the study subjects are: age 59+/-8 years, duration of diabetes 15+/-9 years, height 168+/-11 cm (5 ft 6 in), weight 87+/-19 kg (192 lb), body mass index 31+/-7 kg/m(2), blood pressure 156+/-18 mmHg/85+/-11 mmHg, serum creatinine 150+/-53 micromol/l (1.7+/-0.6 mg/dl), creatinine clearance 66+/-34 ml/min and 24 h urine protein 4.0+/-3.5 g/day.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Self-citation
Research works printed but not linked: 21
- Breyer JA. Therapeutic interventions for nephropathy in type I diabetes mellitus. Semin Nephrol1997; 17: 114–123
- Rodby RA. Type II diabetic nephropathy: its clinical course and therapeutic implications. Semin Nephrol1997; 17: 132–147
- Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med1993; 118: 129–138 · DOI · Paper page
- Viberti G, Mogensen CE, Groop LC, Pauls JF, for the European Microalbuminuria Captopril Study Group. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. J Am Med Assoc1994; 271: 275–279 · doi:10.1001/jama.271.4.275 · Paper page
- Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. Br Med J1991; 303: 81–87 · DOI · Paper page
- Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med1993; 118: 577–581 · DOI · Paper page
- Rodby RA. Antihypertensive treatment in nephropathy of type II diabetes: role of the pharmacologic blockade of the renin–angiotensin system. Nephrol Dial Transplant1997; 12: 1095–1096 · doi:10.1093/ndt/12.6.1095
- Lachin J, Foulkes M. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patients entry, losses to follow-up, noncompliance, and stratification. Biometrics1986; 42: 507–519 · DOI · Paper page
- Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc1958; 53: 457–481 · DOI · Paper page
- Cox DR. Regression models and life-tables. J R Stat Soc Ser B1972; 34: 187–202 · DOI · Paper page
- American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care1997; 20: S5–S13 · DOI
- Geiger H. Are angiotensin II receptor blockers superior to angiotensin converting enzyme inhibitors with regard to their renoprotective effect? Nephrol Dial Transplant1997;12: 640–642 · doi:10.1093/ndt/12.4.640
- Ichikawa I. Will angiotensin II antagonists be renoprotective in humans? Kidney Int1996; 50: 684–692 · DOI
- Hollenberg NK, Fisher NDL. Renal circulation and blockade of the renin–angiotensin system. Is angiotensin-converting enzyme inhibition the last word? Hypertension1995; 26: 602–609 · doi:10.1161/01.hyp.26.4.602
- Bakris GL. The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states. J Am Soc Nephrol1991; 2: S21–S29 · doi:10.1681/asn.v22s21
- Demarie BK, Bakris GL. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med1990; 113: 987–988 · DOI · Paper page
- Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med1990; 112: 707–708 · DOI · Paper page
- Estacio RO, Jeffers BW, Hiatt WR. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med1998; 338: 645–652 · DOI · Paper page
- Cutler JA. Calcium-channel blockers for hypertension—uncertainty continues (editorial). N Engl J Med1998; 338: 679–681 · DOI
- Lewis EJ. Introduction, prevention of diabetic nephropathy. Semin Nephrol1997; 17: 77–79
- Rodby R, Firth L, Lewis E. An economic analysis of captopril in the treatment of diabetic nephropathy. Diabetes Care1996; 19: 1051–106 · DOI
Cited by
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Self-citationStaessen, J. A., Wang, J.-G., & Thijs, L. (2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00002 · Cited by 487
Berl, T., Hunsicker, L. G., Lewis, J. B., Pfeffer, M. A., Porush, J. G., Rouleau, J.-L., Drury, P. L., Esmatjes, E., Hricik, D., Parikh, C. R., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-7-200304010-00010 · Cited by 402
Self-citationPohl, M. A., Blumenthal, S., Cordonnier, D. J., De Alvaro, F., DeFerrari, G., Eisner, G., Esmatjes, E., Gilbert, R. E., Hunsicker, L. G., de Faria, J. B. L., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004110919 · Cited by 375
Self-citationBerl, T., Hunsicker, L. G., Lewis, J. B., Pfeffer, M. A., Porush, J. G., Rouleau, J.-L., Drury, P. L., Esmatjes, E., Hricik, D., Pohl, M., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004090763 · Cited by 322
Self-citation
Metadata
- Authors
- Rodby, R. A., Rohde, R. D., Clarke, W. R., Hunsicker, L. G., Anzalone, D. A., Atkins, R. C., Ritz, E., & Lewis, E. J.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-04-01
- Volume
- 15
- Issue
- 4
- Pages
- 487-497
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2110837983
- Cited by
- 131
- References
- 2
- FWCI
- 9.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. https://app.cochat.ai/papers/10.1093/ndt/15.4.487
- The paper
- Rodby, R. A., Rohde, R. D., Clarke, W. R., Hunsicker, L. G., Anzalone, D. A., Atkins, R. C., Ritz, E., & Lewis, E. J. (2000). The Irbesartan Type II Diabetic Nephropathy Trial: study design and baseline patient characteristics. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/15.4.487
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.